Navigation Links
Children's Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
Date:11/9/2007

PITTSBURGH Nov. 9, 2007 Researchers at Childrens Hospital of Pittsburgh of UPMC are participating in an international clinical trial currently underway to study the effectiveness of oral insulin in preventing or delaying the onset of type 1 diabetes in people at risk for the disease.

The researchers want to determine if one insulin capsule taken daily can prevent or delay the onset of type 1 diabetes in relatives of people who are found to be at risk for developing the disease, according to Dorothy Becker, MBBCh, chief of the Division of Pediatric Diabetes and Endocrinology at Childrens and principal investigator of the study.

An earlier trial called Diabetes Prevention Trial 1, conducted at Childrens and other centers around the world, suggested that oral insulin might delay type 1 diabetes by about four years in some people with auto-antibodies to insulin in their blood. Oral insulin has no known side effects.

Type 1 diabetes is a very difficult disease to manage. Because it typically begins in childhood or young adulthood, and if not properly controlled with insulin injections and diet and exercise, diabetes can lead to a lifetime of complications that can cause chronic disability and be life-threatening, said Dr. Becker. If oral insulin could delay the onset or prevent the disease, we could spare these patients years of difficult management and potential complications such as heart disease and vision loss.

The oral insulin study is being conducted at more than 150 sites throughout the world by TrialNet, a network of diabetes research centers of which Childrens and UPMC are members. At Childrens, researchers plan to enroll at least 30 relatives of patients with type 1 diabetes (parents, siblings, children, cousins, uncles and aunts) ages 3 45 to study the effectiveness of oral insulin.

The belief is that insulin introduced via the digestive tract may induce tolerance, quieting the immune systems attack on itself, said Dr. Becker, also a professor of Pediatrics at the University of Pittsburgh School of Medicine.

In type 1 diabetes, a persons own immune cells destroy the beta cells of the pancreas. Beta cells sense blood glucose and produce insulin, which regulates glucose and turns it into energy. This attack on beta cells begins well before a person develops diabetes and continues long after the disease is diagnosed. Scientists dont know what causes the attack, but the result is the insulin production decreases dramatically. When this happen, glucose builds up in the blood, but the bodys cells starve to death.

About 5 to 10 percent of the nearly 21 million people with diabetes have type 1, formerly known as juvenile onset diabetes or insulin-dependent diabetes. Type 1 diabetes tends to arise in children and young adults but also is diagnosed in older people. Patients need three or more insulin injections a day or treatment with an insulin pump to maintain blood glucose control.


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related biology news :

1. Study finds environmental tests help predict hospital-acquired Legionnaires disease risk
2. Seattle Childrens Hospital leads $23.7 million NIH grant to study gene repair
3. 3 out of 4 hospital patients suffer from malnutrition regardless of their pathology
4. Nationwide Childrens Hospital involved in expanded access program for treatment of PKU
5. Studying component parts of living cells with carbon nanotube cellular probes
6. Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
7. Researchers studying how singing bats communicate
8. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
9. Neuronal conduction of excitation without action potentials based on ceramide production
10. To maximize biofuel potential, researchers look for sorghums sweet spot
11. Joslin researchers uncover potential role of leptin in diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 7, 2017   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... innovative, highly flexible and award winning eClinical solution, is ... iMedNet is a proven Software-as-a-Service (SaaS) clinical research ... (EDC), but also delivers an entire suite of eClinical ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... , Feb 17, 2017 Research and ... Strategic Business Report" report to their offering. ... The report provides separate comprehensive ... Europe , and Rest of World. Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/17/2017)...  If only one in every hundred cells ... to chemotherapy, thousands of cancer cells would remain ... finding these mutations in ever-smaller subpopulations of tumor ... in blood — to guide treatment decisions and ... however, detecting these genetic anomalies may be more ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has ... at the agricultural industry. Pilot studies are about to get under way for the ... Data and 5G innovations. The concept is expected to be transferred eventually to other ...
(Date:2/16/2017)... GREENWICH, Conn. , Feb. 16, ... focused on venture growth investments in biotechnology and ... Josh Richardson , M.D. to Managing Director. ... companies.  He is a board observer at InfaCare ... Longitude,s investments in Aimmune Therapeutics, Akebia Therapeutics, Cadence ...
Breaking Biology Technology: